

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 0492611-0505	In re Application No. 10/668,045
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Chau et al.	
				Filing Date: September 22, 2003	Group:

U.S. PATENT DOCUMENTS					
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass

U.S. PATENT APPLICATIONS					
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No

OTHER DOCUMENTS	
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
<div style="font-size: 2em; font-family: cursive;">g/h</div>	Guu, et al., "Synthesis and Biological Properties of Antitumor-Active Conjugates of ADR with Dextran", <i>J. Biomater. Sci. Polymer Edn</i> , 13 (10): 1135-1151, 2002.
	Harada, et al., "Determinants for the Drug Release from T-0128, Camptothecin Analogue-Carbomethyl Dextran Conjugate", <i>J. Control Release</i> , 69 (3): 399-412, 2000.
	Langer, Robert, "Drugs on Target", <i>Science</i> , 293 : 58-59, 2001.
	Langer, Robert, "Drug Delivery and Targeting", <i>Nature</i> , 392 : 5-10, 1998.
	Langer, et al., "Peptides as Carrier for Tumor Diagnosis and Treatment", <i>Curr. Med. Chem.- Anti Cancer Agents</i> , 1 : 71-93, 2001.
	Pechar, et al., "Poly(Ethylene Glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin", <i>Bioconjugate Chemistry</i> , 11 (2): 131-139, 2000.
	Yui, et al., "Inhibitory Effect of Supramolecular Polyrotaxane -Dipeptide Conjugates on Digested Peptide Uptake via Intestinal Human Peptide Transporter", <i>Bioconjugate Chem.</i> 13 : 582-587, 2002.
<div style="font-size: 2em; font-family: cursive;">g/h</div>	International Search Report issued for corresponding PCT application PCT/US03/29898.

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 0492611-0505	In re Application No. 10/668,045
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Chau et al.	
Filing Date: September 22, 2003				Group: NYA	

U.S. PATENT DOCUMENTS					
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
JA	6,372,205	Duncan et al.	April 16, 2002	424	78.17
JA	6,361,774	Griffiths et al.	March 26, 2002	424	178.1
JA	5,037,883	Kopecek et al.	August 6, 1991	525	54.1

U.S. PATENT APPLICATIONS					
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No

OTHER DOCUMENTS	
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
JA	Bagshawe, et al., "First Clinical Experience with ADEPT", <i>Adv. Drug. Delivery Rev.</i> 22(3): 365-367, 1996.
JA	Burger, et al., "Pre-Clinical Evaluation of a Methotrexate-Albumin Conjugate (MTX-HSA) In Human Tumor Xenografts in Vivo", <i>International Journal of Cancer</i> , 92: 718-724, 2001.
JA	Chau, et al., "Important Factors in Designing Targeted Delivery of Cancer Therapeutics via MMP-2 Mediation", Abstract from 2nd International Symposium on Tumor Targeted Delivery Systems, September 2002.
JA	Chau, et al., "A Novel Polymer-Peptide-Drug Conjugate for Tumor Targeting via MMP-2 Mediation". Abstract from 7th US-Japan Symposium on Drug Delivery Systems, December 2003.
JA	Danhauser-Riedel, et al., "Phase-I Clinical and Pharmacokinetic Trial of Dextran Conjugated Doxorubicin (AD-70, DOX-OXD)", <i>Investigational New Drugs</i> , 11(2-3): 187-195, 1993.
JA	Duncan, et al., "Preclinical Evaluation of Polymer-Bound Doxorubicin", <i>J. Controlled Release</i> , 19: 331-346, 1992.
JA	Duncan, et al., "Design of Oligopeptide Side Chains in Poly N-(2-Hydroxypropyl) Methacrylamide Copolymers to Promote Efficient Degradation by Lysosomal Enzyme", <i>Makromol. Chem.</i> 184: 1997-2008, 1983.

Form PTO-1449 (REV. 8-83) U.S. Department of Commerce Patent and Trademark Office DEC 22 2003 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Atty. Docket: 0492611-0505	In re Application No. 10/668,045
		Applicant: Chau et al.	
		Filing Date: September 22, 2003	Group: NYA
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)		
ga	Duncan, et al., "Polymer-Drug Conjugates, PDEPT and PELT: Basic Principles for Design and Transfer from the Laboratory to Clinic", <i>Journal of Controlled Release</i> , 74(1-3): 135-146, 2001.		
	Flanagan, et al., "Evaluation of Protein-N-(2-Hydroxypropyl) Methacrylamide Copolymer Conjugates as Targeted Drug-Carriers. 2. Body Distribution of Conjugates Containing Transferrin, Antitransferrin Receptor Antibody or Anti-Thy 1.2 Antibody and Effectiveness of Transferrin-Containing Daunomycin Conjugates Against Mouse L1210 Leukaemia in Vivo", <i>Journal of Controlled Release</i> , 18: 25-38, 1992.		
	Garsky, et al., "The Synthesis of a Prodrug of Doxorubicin Designed to Provide Reduced Systemic Toxicity and Greater Target Efficacy", <i>Journal of Medicinal Chemistry</i> , 44: 4216-4224, 2001.		
	Hoes, et al., "Biological Properties of Adriamycin Bound to Biodegradable Polymeric Carriers", <i>J. Controlled Release</i> , 23: 37-54, 1993.		
	Matsumura, et al., "A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumorotropic Accumulation of Proteins and the Antitumor Agent Smancs", <i>Cancer Research</i> , 46: 6387-6392, 1986.		
	Munehika, et al., "Tissue Distribution and Macromolecular Conjugate, Adriamycin Linked to Oxidized Dextran, in Rat and Mouse Bearing Tumor Cells", <i>Biol. Pharm. Bull.</i> 17(9): 1193-1198, 1994.		
	Noguchi, et al., "Tumor Localization and in vivo Antitumor Activity of the Immunoconjugate Composed of Anti-Human Colon Cancer Monoclonal Antibody and Mitomycin C-Dextran Conjugate", <i>Japanese J. Cancer Res.</i> 82: 219-226, 1991.		
	Nogusa et al., "Distribution Characteristics of Carboxymethylpullulan-Peptide Doxorubicin Conjugates in Tumor-Bearing Rats: Different Sequences of Peptide Spacers and Doxorubicin Contents", <i>Biol. Pharm. Bull.</i> 23(5): 621-626, 2000.		
	Nogusa, et al., "Antitumor Effects and Toxicities of Carboxymethylpullulan-Peptide-Doxorubicin Conjugates", <i>Biol. Pharm. Bull.</i> 20(10): 1061-1065, 1997.		
	Park, et al., "Fibroblast Activation Protein, A Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts", <i>J. Biol. Chem.</i> 274(51): 36505-36512, 1999.		
	Pechar, et al., "Conjugates of Antibody-Targeted PEG Multiblock Polymers with Doxorubicin in Cancer Therapy", <i>Macromolecular Bioscience</i> , 3: 364-372, 2003.		
	Pimm, et al., "Gamma Scintigraphy of the Biodistribution of I-123-Labelled N-(2-Hydroxypropyl) Methacrylamide Copolymer-Doxorubicin Conjugates in Mice with Transplanted Melanoma and Mammary Carcinoma", <i>J. Drug Targeting</i> , 3(5): 375, 1996.		
ga	Putnam, et al., "Polymer Conjugates with Anticancer Activity", <i>Advances in Polymer Sciences</i> , 122: 55-123, 1995.		

Form PTO-1449 (REV. 8-83) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Atty. Docket: 0492611-0505	In re Application No. 10/668,045
		Applicant: Chau et al.	
		Filing Date: September 22, 2003	Group: NYA
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Rejmanova, et al., "Stability in Plasma and Serum of Lysosomally Degradable Oligopeptide Sequences in N-(2-Hydroxypropyl)Methacrylamide Copolymers", <i>Biomaterials</i> , 6: 45-48, 1985.		
	Rejmanova, et al., "Degradation of Oligopeptide Sequences in N-(2-Hydroxypropyl)Methacrylamide Copolymers by Bovine Spleen Cathepsin B", <i>Makromol. Chem.</i> 184: 2009-2020, 1983.		
	Seftor, et al., "Chemically Modified Tetracyclines Inhibit Human Melanoma Cell Invasion and Metastasis" <i>Clinical & Experimental Metastasis</i> , 16(3): 217-225, 1998.		
	Seymour, et al., "The Pharmacokinetics of Polymer-Bound Adriamycin", <i>Biochemical Pharmacology</i> , 39(6): 1125-1131, 1990.		
	Seymour, et al., "Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin", <i>Journal of Clinical Oncology</i> , 20: 1668-1676, 2002.		
	Song, et al., "Pharmacokinetic Characteristics and Antitumor Activity of the N-Succinyl-Chitosan-Mitomycin C Conjugate and the Carboxymethyl-Chitin-Mitomycin C Conjugate", <i>Biol. Pharm. Bull.</i> 16(1): 48-54, 1993.		
	Takakura, et al., "Macromolecular Carrier Systems for Targeted Drug Delivery: Pharmacokinetic Considerations on Biodistribution", <i>Pharmaceutical Res.</i> , 13(6), 820-831, 1996.		
	Tang, et al., "Binding and Cytotoxicity of HPMa Copolymer Conjugates to Lymphocytes Mediated by Receptor-Binding Epitopes", <i>Pharmaceutical Research</i> , 20: 360-367, 2003.		
	Trouet, et al., "A Covalent Linkage Between Daunorubicin and Proteins that is Stable in Serum and Reversible by Lysosomal Hydrolases, as Required for A Lysosomotropic Drug-Carrier Conjugate: In Vitro and In Vivo Study", <i>Proc. Natl. Acad. Sci. USA</i> , 79: 626-629, 1982.		
	Ulbrich, et al., "Poly(Ethylene Glycol)s Containing Enzymatically Degradable Bonds", <i>Makromol. Chem.</i> 187: 1131-1144, 1986.		
	Yokoyama, et al., "Toxicity and Antitumor Activity Against Solid Tumors of Micelle-Forming Polymeric Anticancer Drug and its Extremely Long Circulation in Blood", <i>Cancer Research</i> , 51: 3229-3236, 1991.		
	Ziober, et al., "Type I Collagen Degradation by Invasive Oral Squamous Cell Carcinoma", <i>Oral Oncology</i> , 36(4): 365-372, 2000.		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			